2021
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaOverall response rateMedian progression-free survivalProgression-free survivalT-cell lymphomaOverall survivalR Peripheral T Cell LymphomaResponse rateFollicular helper cell phenotypeMulticenter phase 2 studyHigher overall response rateFrequent grade 3Complete response rateComplete remission ratePhase 2 studyPhase 1 trialDuration of responseHelper cell phenotypeLonger median survivalHistone deacetylase inhibitorsPTCL patientsR diseaseTreatment-naïveMedian survivalRemission rate
2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderDiffuse large B-cell lymphomaMonomorphic post-transplant lymphoproliferative disorderProgression-free survivalMedian progression-free survivalOverall survivalR-CHOPR-EPOCHGerminal centersCell of originImmunosuppressive therapyEBV infectionLymphoproliferative disordersTerms of PFSBetter progression-free survivalDLBCL subtypesCommon first-line therapySeattle GeneticsDiffuse large B-cell lymphoma (DLBCL) subtypeLarge B-cell lymphomaMonths-24 yearsComplete response rateMedian overall survivalPrimary refractory diseaseFirst-line therapy
2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.Peer-Reviewed Original ResearchAutologous stem cell transplantProgression-free survivalRefractory Hodgkin lymphomaComplete response rateDose limiting toxicitiesHigh-dose chemotherapyOverall response rateHodgkin's lymphomaBrentuximab vedotinOverall survivalDay 1Partial responseMedian numberDose levelsPrior autologous stem cell transplantResponse rateAutologous stem cell transplantationSeattle GeneticsPhase II dosePhysician's choice chemotherapyPrior radiation therapyPrior systemic therapyLong-term respondersSubset of patientsEvidence of relapse
2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cell
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerologyClinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.
Arcaini L, Paulli M, Burcheri S, Boveri E, Rossi A, Spina M, Passamonti F, Montanari M, Gallamini A, Uziel L, Crugnola M, Montanari F, Pascutto C, Morra E, Lazzarino M. Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour. Blood 2006, 108: 2427. DOI: 10.1182/blood.v108.11.2427.2427.Peer-Reviewed Original ResearchMarginal zone B-cell lymphomaPrimary nodal marginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaEvent-free survivalB-cell lymphomaShorter event-free survivalPrimary nodal marginal zone lymphomaFLIPI scoreMarginal zone lymphomaNodal marginal zone lymphomaClinical featuresB symptomsHCV serologyOverall survivalBorderline significancePrognostic assessmentLower riskRare diseaseMedian age 63 yearsPeripheral blood involvementAge 63 yearsPositive HCV serologyWorse overall survivalOverall response rateLymph node localizationPrevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.Peer-Reviewed Original ResearchConceptsHCV-positive patientsMarginal zone B-cell lymphomaHCV-negative patientsEvent-free survivalHCV infectionMarginal zone lymphomaB-cell lymphomaOverall survivalHigh prevalenceMost HCV-positive patientsHepatitis C virus infectionC virus infectionBone marrow involvementOverall response rateMALT sitesHCV serostatusAdvanced diseasePresenting featuresHCV serologyMarrow involvementOrgan involvementPoor OSAntiviral treatmentIndolent courseHistological diagnosis